EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post‐transplant cyclophosphamide era: A GETH ‐ TC study

Marta Peña iD, Lorenzo Lazzari iD, Diego F Martínez, Fabio Ciceri iD, Aitana Balaguer-Roselló, Jaime Sanz, Maria J Pascual, Ana Benzaquén iD, José L Piñana, Maria Q Salas, Agustin Nieto-Vazquez, Ignacio Español und 9 weitere

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70367 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Marta Peña und 20 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Barcelona, Spain. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Lymphoma, Transplantation Conditioning, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Gebro Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic haematopoietic cell transplantation (alloHCT) remains a potentially curative strategy for relapsed or refractory lymphoid malignancies, even in the post‐chimeric antigen receptor T‐cell and bispecific antibody era. While reduced‐intensity conditioning regimens offer lower non‐relapse mortality (NRM), relapse rates remain high, and optimal conditioning strategies in the setting of post‐transplant cyclophosphamide (PTCy) prophylaxis remain undefined. In this retrospective, international multicentre study, the primary end‐point was NRM. We compared treosulfan/fludarabine (Treo/Flu) versus thiotepa/busulfan/fludarabine (TBF) in 178 adults with lymphoid malignancies undergoing first alloHCT with PTCy and peripheral blood grafts. Three‐year NRM was 14.0% with Treo/Flu versus 33.0% with TBF. On multivariate analysis, Treo/Flu was associated with significantly lower 3‐year NRM (hazard ratio [HR] 0.44; 95% confidence interval [CI], 0.22–0.87; p = 0.018). Conditioning regimen was not independently associated with overall survival (OS) or progression‐free survival (PFS), and relapse incidence was similar between regimens. Moderate to severe chronic graft‐versus‐host disease (GVHD) was higher with Treo/Flu (26.0% vs. 9.9%; HR 2.43; 95% CI, 1.09–5.43; p = 0.03), while GVHD‐free/relapse‐free survival (GFRS) was comparable. Findings were consistent in a prespecified propensity score‐matched sensitivity analysis. These findings support Treo/Flu as a potentially safer reduced‐toxicity conditioning option than TBF in the context of PTCy‐based GVHD prophylaxis for lymphoid malignancies and warrant prospective validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationLymphomaTransplantation ConditioningAntineoplastic Combined Chemotherapy ProtocolsHumansVidarabineBusulfanThiotepaFemaleCyclophosphamideMaleMiddle AgedRetrospective StudiesAdultTransplantation, HomologousAgedGraft vs Host Disease

Stichwörter der Autor:innen

allogeneic haematopoietic cell transplantationlymphoid malignanciespost‐transplant cyclophosphamidereduced‐intensity conditioningtreosulfan/fludarabine

Substanzen

VidarabineBusulfanfludarabinetreosulfanThiotepaCyclophosphamide

Autor:innen und Institutionen

  • Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Barcelona, Spain.
  • Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Department of Hematology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
  • Hematology Department, Hospital Regional Universitario de Málaga, Málaga, Spain.
  • Hematology Department, Hospital Clínico Universitario de Valencia-INCLIVA, Valencia, Spain.
  • Hematopoietic Cell Transplantation Unit, Hospital Clínic de Barcelona, ICHMO, Barcelona, Spain.

ORCID-Profile: Marta Peña, Lorenzo Lazzari, Fabio Ciceri, Ana Benzaquén, Raffaella Greco

Förderung

  • Gebro Pharma

Zitieren

APA

Peña, M., Lazzari, L., Martínez, D. F., Ciceri, F., Balaguer-Roselló, A., Sanz, J., Pascual, M. J., Benzaquén, A., Piñana, J. L., Salas, M. Q., Nieto-Vazquez, A., Español, I., Huguet, M., Bento, L., Saez, A. J., Barba, P., Filaferro, S., Carbonell Asins, J. A., Peña, C., …, & Greco, R. (2026). Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post‐transplant cyclophosphamide era: A GETH ‐ TC study. British Journal of Haematology. https://doi.org/10.1111/bjh.70367

Vancouver

Peña M, Lazzari L, Martínez DF, Ciceri F, Balaguer-Roselló A, Sanz J, et al. Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post‐transplant cyclophosphamide era: A GETH ‐ TC study. British Journal of Haematology. 2026. doi:10.1111/bjh.70367

BibTeX
@article{Pea2026,
  author = {Peña, Marta and Lazzari, Lorenzo and Martínez, Diego F and Ciceri, Fabio and Balaguer-Roselló, Aitana and Sanz, Jaime and Pascual, Maria J and Benzaquén, Ana and Piñana, José L and Salas, Maria Q and Nieto-Vazquez, Agustin and Español, Ignacio and Huguet, Maria and Bento, Leyre and Saez, Adolfo J and Barba, Pere and Filaferro, Silvia and Carbonell Asins, Juan A and Peña, Carlos and Mussetti, Alberto and Greco, Raffaella},
  title = {Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post‐transplant cyclophosphamide era: A GETH ‐ TC study},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70367}
}
Kostenlos starten →